CDMO Bioconjugation Manufacturing: Advancing Targeted Therapies

Dr. Sesay has over 25 years of biotechnology experience in biologics process development and manufacturing, bioconjugation and modification of biological molecules (including monoclonal and polyclonal antibodies, enzymes, toxins, and others) and small molecules. He also has over 17 years of experience in the Contract Development and Manufacturing (CDMO) sectors. Prior to joining GBI in 2002, Dr. Sesay supervised many projects in R&D, process development, and biologics manufacturing at Life Technologies Inc. (now Thermo Fischer), Kirkegaard and Perry Laboratories (KPL), and Elusys Therapeutics. After receiving his Ph.D. in Biochemistry from the University of London (Queen Mary College), England, Dr. Sesay worked for three years as a postdoctoral candidate at the University of Maryland, College Park in protein purification and characterization. In addition to his responsibilities at GBI, Dr. Sesay is also a member of the advisory committee for the Professional Science Master’s Degree in Medical Biotechnology offered by the College of Health Sciences at Barry University.